The role of clinical metabolomics in the diagnosis of bladder cancer

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Bladder cancer is a widespread disease characterized by high cancer-specific mortality and high cost of treatment. The search for available and reliable biological markers for the early diagnosis of urothelial carcinomas is an urgent task of oncourology. One of the promising ways to improve the efficiency of bladder cancer diagnostics is the use of the possibility of the clinical metabolomics.

AIM: Was to study the possibility of assessing the content of various amino acids and their metabolites in blood serum for the diagnosis of bladder cancer.

MATERIALS AND METHODS: Serum concentrations of 28 amino acids and their metabolites were studied in 18 patients with urothelial cancer and 20 representatives of the control group without an oncological history. History taking, routine oncological screening, and blood sampling for laboratory tests were performed.

RESULTS: Four metabolomes (glycine, phenylalanine, asparagine, and threonine) were identified, the blood serum concentration of which significantly changes in patients with urothelial cancer. These metabolomes can be considered as potential biomarkers of urothelial cancer.

CONCLUSIONS: The study of the serum content of these four amino acids seems to be the most promising for the isolation of a potential biomarker of urothelial cancer.

Full Text

Restricted Access

About the authors

Sergey A. Zamyatnin

Priozersky Interdistrict Hospital

Email: elysium2000@mail.ru
ORCID iD: 0000-0002-8453-2148
SPIN-code: 7024-0062

Dr. Sci. (Med.), Urologist, Chief Physician

Russian Federation, 35, Kalinina st., Priozersk, Leningrad Region, 188760

Anton V. Malushko

Priozersky Interdistrict Hospital

Email: a-malushko@mail.ru
SPIN-code: 5703-0630

Oncologist, Deputy Chief Physician

Russian Federation, 35, Kalinina st., Priozersk, Leningrad Region, 188760

Irina S. Gonchar

Priozersky Interdistrict Hospital

Author for correspondence.
Email: bonechka@mail.ru
ORCID iD: 0000-0003-1702-9849
SPIN-code: 2768-7253

Cand. Sci. (Med.), Urologist

Russian Federation, 35, Kalinina st., Priozersk, Leningrad Region, 188760

References

  1. Al-Attar TKh. Small bowel reconstruction of the urinary organs [dissertation]. Ufa; 2022. 306 p.
  2. Ryndin AA, Zaitseva LA, Shishlo IF, et al. Predicting the likelihood of severe complications in the postoperative period of radical cystectomy. News of surgery. 2018;26(4):447–456. doi: 10.18484/2305-0047.2018.4.447
  3. Sukonko OG, Ryndin AA, Rolevich AI, et al. Predictive model of probability of postoperative 90-day mortality after radical cystectomy. Oncology journal. 2018;12(1(45)):55–62.
  4. Vozianov SA, Shamraev SN, Stus VP, et al. Prediction of early postoperative complications of radical cystectomy with various methods of urinary diversion using mathematical modeling methods. Urology. 2018;22(3(86)):22–30. (In Russ.) doi: 10.26641/2307-5279.22.3.2018.143270
  5. Borzov KA, Valiev AK, Musaev ER, Kulaga AV. Surgical treatment tactics for patients with metastases of renal cancer in the spine. Sarcomas of Bones, Soft Tissues and Skin Tumors. 2018;(2):14–27. (In Russ.)
  6. Zakharova NB, Ponukalin AN, Skriptsova SA. The prospects for application of biomarker “vascular endothelial growth factor” in predicting the treatment outcomes of bladder cancer. Saratov Scientific Medical Journal. 2018;14(2):268–272. (In Russ.)
  7. Jikia EL, Kulinich TM, Zakharenko MV, Bozhenko VK. Molecular markers in non-muscle-invasive bladder cancer. Bulletin of the Russian Scientific Center for Roentgen Radiology. 2019;19(4):63–84. (In Russ.)
  8. Osmanov YuI, Kogan EA, Rapoport LM, et al. Stem cell markers and their prognostic value in urothelial carcinomas of the urinary system. Urology. 2019;2:40–49. (In Russ.) doi: 10.18565/urology.2019.2.40-49
  9. Lokhov PG, Balashova EE, Trifonova OP, et al. Ten years of the Russian metabolomics: history of development and achievements. Biomedical Chemistry. 2020;66(4):279–293. (In Russ.) doi: 10.18097/PBMC20206604279
  10. Govorov IE, Kalinina EA, Sitkin SI, et al. Metabolomic biomarkers of gynecological malignancy. Treatment and Prevention. 2018;8(3):54–60. (In Russ.) doi: 10.1038/nrneph.2011.152
  11. Giannopoulou A, Velentazas A, Konstantakou EG, et al. Revisiting histone deacetylases in human tumorigenesis: the paradigm of urothelial bladder cancer. Int J Mol Sci. 2019;20(6):1291. doi: 10.3390/ijms20061291
  12. Abbaoui B, Lucas ChR, Riedl KM, et al. Cruciferous vegetables, isothiocyanates and bladder cancer prevention. Mol Nutr Food Res. 2018;62(18):1800079. doi: 10.1002/mnfr.201800079
  13. Aalami AH, Abdeahad H, Mesqari M, et al. Urinary angiogenin as a marker for bladder cancer: a meta-analysis. Biomed Res Int. 2021;2021:5557309. doi: 10.1155/2021/5557309
  14. Belyakova LI, Shevchenko AN, Sagakyants AB, Filatova EV. Markers of bladder cancer: their role and prognostic significance (literature review). Oncourology. 2021;17(2):145–156. (In Russ.) doi: 10.17650/17269776-2021-17-2-145-156
  15. Wittmann BM, Stirdivant SM, Mitchell MW, et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 2014;9(12): e115870. doi: 10.1371/journal.pone.0115870
  16. Zavalishina LE, Povilaityte PE, Raskin GA, et al. Assessment of pd-l1 expression in patients with urothelial cancer with contraindications to platinum-based therapy. Malignant tumors. 2019;9(1): 10–15.
  17. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 godu. Kaprin AD, Starinskogo VV, Petrova GV, editors. Moscow: MNIOI im. PA. Gercena — Branch FBGU “NMIRC” Minzdrava Rossii, 2016. 236 p.
  18. Buckwalter JM, Chan W, Shuman Th, et al. Characterization of histone deacetylase expression within in vitro and in vivo bladder cancer model systems. Int J Mol Sci. 2019;20(10):2599. doi: 10.3390/ijms20102599
  19. Karyakin OB, Ivanov SA, Kaprin AD. Bladder cancer: what’s new in 2017–2018. Onkourologiya. 2018;14(4):110–117. doi: 10.17650/1726-9776-2018-14-4-110-117
  20. Ganti Sh, Taylor SL, Aboud OA, et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 2012;72(14):3471–3479. doi: 10.1158/0008-5472.CAN-11-3105
  21. Cheng Y, Yang X, Deng X, et al. Metabolomics in bladder cancer: a systematic review. Int J Clin Exp Med. 2015;8(7):11052–11063.
  22. Patent RU 2586295/ 10.06.2016. Bergmann A, Shtruk Y, Melander O. Biomarkery dlya prognozirovaniya vozniknoveniya raka.
  23. Oeyen E, Hoekx L, de Wachter S, et al. Cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles. Int J Mol Sci. 2019;20(4):821. doi: 10.3390/ijms20040821
  24. Amara ChS, Vantaku V, Lotan Y, Putluri N. Recent advances in the metabolomic study of bladder cancer. Expert Rev Proteomics. 2019;16(4):315–324. doi: 10.1080/14789450.2019.1583105
  25. Piao X, Byun YJ, Kim W, Kim J. Unmasking molecular profiles of bladder cancer. Investig Clin Urol. 2018;59(2):72–82. doi: 10.4111/icu.2018.59.2.72
  26. Humayun-Zakaria N, Arnold R, Goel A, et al. Tropomyosins: potential biomarkers for urothelial bladder cancer. Int J Mol Sci. 2019;20(5):1102. doi: 10.3390/ijms20051102
  27. Liang Q, Zhang G, Li W, et al. Comparison of the diagnostic performance of fluorescence in situ hybridization (FISH), nuclear matrix protein 22 (NMP22), and their combination model in bladder carcinoma detection: a systematic review and meta-analysis. Onco Targets Ther. 2018;12:349–358. doi: 10.2147/OTT.S186065
  28. Chang-sheng X, Chun-hong F, Ming S, et al. Use of the nuclear matrix protein 22 bladder chek test for the detection of primary and recurrent urothelial carcinoma. Dis Markers. 2020;2020:3424039. doi: 10.1155/2020/3424039
  29. Guo A, Wang X, Gao L, et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis. Can Urol Assoc J. 2014;8(5–6):E347–E352. doi: 10.5489/cuaj.1668
  30. Riesz P, Lotz G, Páska C, et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathology & Oncology Research. 2007;13(3):187–194. doi: 10.1007/bf02893498
  31. Vorobtsova IYe, Vasil’yeva ZZH, Kouzova YeD, et al. Diagnosis of recurrent bladder cancer by fluorescence in situ hybridization assay on urine sediment cells. Cancer Urology. 2013;(2):35–41.
  32. Moonen PMJ, Merkx GFM, Peelen P, et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. European Urology. 2007;51(5): 1275–1280. doi: 10.1016/j.eururo.2006.10.044
  33. Szymanska B, Sawicka E, Guzik A, et al. The diagnostic value of nuclear matrix proteins in bladder cancer in the aspect of environmental risk from carcinogens. Biomed Res Int. 2017;2017:9643139. doi: 10.1155/2017/9643139
  34. Werner A, Koschke M, Leuchtner N, et al. Reconstitution of T cell proliferation under arginine limitation: activated human T cells take up citrulline via l-type amino acid transporter 1 and use it to regenerate arginine after induction of argininosuccinate synthase expression. Front Immunol. 2017;8:864. doi: 10.3389/fimmu.2017.00864
  35. Lin J, Juo B, Yeh Y, et al. Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics. BMC Bioinformatics. 2021;22(1):305. doi: 10.1186/s12859-021-04235-z

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The range of deviations in the content of aspartic acid in the blood serum in patients of the 1st and 2nd groups

Download (94KB)
Indexing metadata
3. Fig. 2. The range of deviations in the content of the amino acid threonine in the blood serum in patients of the 1st group, depending on the degree of tumor differentiation and in the control group

Download (110KB)
Indexing metadata
4. Fig. 3. The range of deviations in the content of glycine in the blood serum in patients of the 1st and 2nd groups

Download (82KB)
Indexing metadata

Copyright (c) 2022 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies